This study observed the anti-cancer activity of recombinant bromelain produced by the DNA recombinant technology thus easing the purification steps. The in-vitro cytotoxicity assay was conducted on the recombinant bromelain treated and untreated breast cancer (MCR-7) and normal cell lines (Vero). Then the half maximal inhibitory concentration (IC50) on all samples were recorded. Commercial bromelain served as a control in this experiment. The IC50 for both enzymes are 0.29mg/mL and 0.27mg/mL for recombinant and commercial bromelain respectively. Based on the IC50 values, both recombinant and commercial bromelain, did affect the cell lines at high concentration which is more than 0.25 mg/mL. zthe IC50 obtained from MCF-7 cells treated with recombinant and commercial bromelain are 0.20mg/mL and 0.16mg/mL respectively. Therefore, recombinant bromelain behaves similarly to the commercial bromelain in their anti-cancer activity especially to the MCF-7 breast cancer and Vero cells lines.